Aldeyra Therapeutics, Inc.’s reproxalap has shown significant symptom improvement over Novartis AG’s Xiidra in a Phase II dry eye trial, prompting the firm to tout its potential as a first-line treatment while available products continue to grapple with discontinuation problems.
The combination of rapid activity and improved tolerability evidenced by reproxalap has the potential to address significant compliance issues with...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)